Ontology highlight
ABSTRACT:
SUBMITTER: Hutmacher MM
PROVIDER: S-EPMC5445230 | biostudies-literature | 2017 May
REPOSITORIES: biostudies-literature
Hutmacher M M MM Papp K K Krishnaswami S S Ito K K Tan H H Wolk R R Valdez H H Mebus C C Rottinghaus S T ST Gupta P P
CPT: pharmacometrics & systems pharmacology 20170320 5
Tofacitinib is an oral Janus kinase inhibitor. An integrated analysis was conducted to evaluate dosage optimality for tofacitinib in patients with moderate-to-severe plaque psoriasis and the impact of body weight on optimality in this patient population. Data were pooled from one phase IIb trial (2, 5, and 15 mg twice daily (b.i.d.)) and four phase III trials (5 and 10 mg b.i.d.). A longitudinal exposure-response model for Psoriasis Area and Severity Index (PASI) improvement (percent change from ...[more]